Darwin Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Darwin Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.62K	Buy	+27	New	+$1.7K	﹤0.01%	936
2025 Q2	–	Sell	-35	Closed	-$2.3K	–	617
2025 Q1	$2.3K	Hold	35	–	–	﹤0.01%	506
2024 Q4	$2.3K	Hold	35	–	–	﹤0.01%	506
2024 Q3	$2.46K	Buy	+35	New	+$2.93K	﹤0.01%	515
2020 Q2	–	Sell	-110	Closed	-$9K	–	218
2020 Q1	$9K	Buy	+110	New	+$9.48K	﹤0.01%	486

Other funds holding BMRN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return

Edmond de Rothschild Holding Chambesy, Switzerland $8.18B AUM 23.81% 1-Year Est. Return

Darwin Wealth Management's BMRN Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2026: 27 shares worth $1.62K. The stake represents ﹤0.01% of the portfolio and ranks #936 among its holdings. This is a return to the name: Darwin Wealth Management previously reported a position in BMRN as recently as Q1 2025.

Darwin Wealth Management first reported a position in BMRN in Q1 2020 and has held it in 5 quarters since. The position peaked at $9K in Q1 2020. 308 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Darwin Wealth Management held 27 shares of BioMarin Pharmaceuticals worth $1.62K as of Q3 2026.
BioMarin Pharmaceuticals was a new Darwin Wealth Management position in Q3 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #936 holding.
Darwin Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2020 and has held it in 5 quarters since.
Darwin Wealth Management's BioMarin Pharmaceuticals position peaked at $9K in Q1 2020.
308 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.